Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I

@article{Husebye2009ClinicalMA,
  title={Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I},
  author={E. S. N. Husebye and Jaakko Perheentupa and Riina Rautemaa and Olle K{\"a}mpe},
  journal={Journal of Internal Medicine},
  year={2009},
  volume={265}
}
Autoimmune polyendocrine syndrome type I (APS‐I) is a monogenic model disease of autoimmunity. Its hallmarks are chronic mucocutaneous candidosis, hypoparathyroidism and adrenal insufficiency, but many other autoimmune disease components occur less frequently. The first components usually appear in childhood, but may be delayed to adolescence or early adult life. There is enormous variation in presentation and phenotype, which makes the diagnosis difficult. Antibodies against interferon‐ω and… Expand
A Longitudinal Follow-up of Autoimmune Polyendocrine Syndrome Type 1
TLDR
Multiple presumable autoimmune manifestations, in particular hypoparathyroidism, CMC, and enamel hypoplasia, should prompt further diagnostic workup using autoantibody analyses (eg, interferon-ω) and AIRE sequencing to reveal APS1, even in adults. Expand
Late-onset autoimmune polyendocrine syndrome type 1: a case report and literature review
TLDR
A late-onset Chinese case who presented with symptoms of persistent tetany due to hypocalcemia is described, and next-generation sequencing identified a known homozygous AIRE mutation (p.R139X). Expand
Autoimmune polyendocrine syndrome type 1: an Italian survey on 158 patients
TLDR
In Italy, APS-1 is a rare disorder presenting with the three major manifestations and associated with different AIRE gene mutations and other organ-specific autoantibodies are markers of clinical, subclinical or potential autoimmune conditions. Expand
Expanding the Phenotypic and Genotypic Landscape of Autoimmune Polyendocrine Syndrome Type 1
TLDR
The spectrum of phenotypes and AIRE mutation in APS‐1 has been expanded and Assay of interferon antibodies is a robust screening tool for APs‐1. Expand
Autoimmune polyendocrine syndrome type 1: an extensive longitudinal study in Sardinian patients.
TLDR
The single AIRE mutation, R139X, and the anti-IFN-ω and IFN-α autoantibodies are helpful for earlier diagnosis, especially when APS1 presents unusually. Expand
Polyglandular Autoimmune Syndrome Type I
TLDR
This is a potentially underdiagnosed condition due to the rarity and enormous variability in its presentation, which requires collaboration among multiple specialties because of the multiplicity of organs affected. Expand
Cutaneous vasculitis in patients with autoimmune polyendocrine syndrome type 1: report of a case and brief review of the literature
TLDR
This case suggests that cutaneous vasculitis may represent a first sign of autoimmune polyendocrine syndrome type 1 and children presenting with unexplained vasculitic skin rash should be followed-up in order to early identify APS 1. Expand
The immunobiology and clinical features of type 1 autoimmune polyglandular syndrome (APS-1).
TLDR
A detailed critical overview of the study history, epidemiology, clinical features, and related mechanisms of autoimmunity in APS-1, as well as currently available therapies for this autoimmune disorder is provided. Expand
Anti-Cytokine Autoantibodies Preceding Onset of Autoimmune Polyendocrine Syndrome Type I Features in Early Childhood
TLDR
This is the first study to collate the onset of clinical features, cytokine and endocrine autoantibodies in APS-I infants and siblings and hint at some more sharply focused early event(s) in autoimmunization. Expand
A Review of Autoimmune Enteropathy and Its Associated Syndromes
TLDR
Diagnosis and treatment is challenging, and further research is needed to better understand the pathogenesis, disease progression, and long-term outcomes of these conditions. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 64 REFERENCES
Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I.
TLDR
Precocious persistent antibodies found in patients with thymoma and/or myasthenia gravis show 98% or higher sensitivity and APS-I specificity and are thus a simpler diagnostic option than detecting AIRE mutations. Expand
Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen.
TLDR
NALP5 appears to be a tissue-specific autoantigen involved in hypoparathyroidism in patients with APS-1 and may be diagnostic for this prominent component of APs-1. Expand
Neurologic consequences of autoimmune polyglandular syndrome type 1
TLDR
A patient with a previously undescribed autoimmune cerebellar degeneration occurring in association with APS-1 is reported with gait ataxia associated with band-like hyperintense signal abnormalities of both Cerebellar hemispheres and a unique antibody to cerebellAR Purkinje cells and brainstem neurons. Expand
Autoimmune polyendocrine syndrome type 1 in Norway: phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator gene.
TLDR
The clinical features and the AIRE mutations are more diverse in the Norwegian population than previously thought, and some patients with APS I clinically resemble those from Finland and other European countries, but some have milder phenotypes. Expand
Effector Mechanisms of the Autoimmune Syndrome in the Murine Model of Autoimmune Polyglandular Syndrome Type 11
TLDR
It is shown that T cells are indispensable to the breakdown of self-tolerance, in contrast to B cells which play a more limited role in autoimmunity, and therapies targeted specifically at the CD4+ T cell subset may help control autoimmune disease in patients with APS1. Expand
Pituitary autoantibodies in autoimmune polyendocrine syndrome type 1
TLDR
TDRD6 is identified as a major autoantigen in APS1 patients and several sera from GH-deficient patients stain specific cell populations and nerves in the pituitary gland, which is shown to represent a novel subpopulation of anterior pituitaries. Expand
The hypoparathyroidism of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy protective effect of male sex.
TLDR
A clear gender linkage with lower and later incidence in males is found and whether AIRE is expressed in the human parathyroid is studied, because its absence could be a pathogenetic factor. Expand
Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients.
TLDR
The clinical spectrum in patients with APECED is broad, and the majority of patients have three to five manifestations, some of which may not appear until the fifth decade, therefore, all patients need lifelong follow-up for the detection of new components of the disease. Expand
Candidiasis-endocrinopathy syndrome with progressive myopathy.
TLDR
A women suffering from the candidiasis-endocrinopathy syndrome, developed severe myopathy in her fourth decade and died from it at the age of 37 years, with no convincing evidence of primary autoimmune damage. Expand
Anti-Interferon Autoantibodies in Autoimmune Polyendocrinopathy Syndrome Type 1
TLDR
These apparently spontaneous autoantibody responses to IFNs, particularly IFN-α and IFn-ω, segregate like a recessive trait; their high “penetrance” is especially remarkable for such a variable condition. Expand
...
1
2
3
4
5
...